Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Regulation FD Disclosure

ME Staff 8-k
-
0
Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Regulation FD Disclosure

Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure.

On October 6, 2018, Blueprint Medicines Corporation issued a press release announcing the presentation of updated data for RET-altered medullary thyroid cancer (“MTC”) patients and papillary thyroid cancer patients from its ongoing Phase 1 ARROW clinical trial evaluating BLU-667 for the treatment of RET-altered non-small cell lung cancer, MTC and other advanced solid tumors. The data were presented on Saturday, October 6, 2018 in an oral presentation at the 88thAnnual Meeting of the American Thyroid Association (the “ATA Annual Meeting”)in Washington, D.C.A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K, and a copy of the presentation at the ATA Annual Meeting is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits.


Blueprint Medicines Corp Exhibit
EX-99.1 2 ex-99d1.htm EX-99.1 bpmc_Ex99_1 Exhibit 99.1   Blueprint Medicines Announces Updated Data from Phase 1 ARROW Clinical Trial Showing Broad,…
To view the full exhibit click here

About Blueprint Medicines Corporation (NASDAQ:BPMC)

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options. The Company has developed a small molecule drug pipeline in cancer and a genetic disease. The Company’s drug candidate, BLU-285, targets KIT Exon 17 mutants and PDGFRa D842V, which are abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. It is engaged in developing BLU-285 for patients with systemic mastocytosis (SM), a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor (GIST). Its drug candidate, BLU-554, targets FGFR4, a kinase that is aberrantly activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma (HCC).